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hibitors	 (ACEIs)/angiotensin	 receptor	 blockers	 (ARBs)	 on	 COVID-19	 clinical	 out-
comes. We aimed to provide a comprehensive/updated evaluation of the effect 
of	 ACEIs/ARBs	 on	 COVID-19-related	 clinical	 outcomes,	 including	 exploration	 of	
interclass	 differences	 between	ACEIs	 and	 ARBs,	 using	 a	 systematic	 review/meta-
analysis	approach	conducted	in	Medline	(OVID),	Embase,	Scopus,	Cochrane	library,	
and	medRxiv	from	inception	to	22	May	2020.	English	studies	that	evaluated	the	ef-
fect	 of	 ACEIs/ARBs	 among	 patients	with	COVID-19	were	 included.	 Studies’	 qual-
ity	was	appraised	using	the	Newcastle-Ottawa	Scale.	Data	were	analyzed	using	the	




and	 death	 (OR:0.97,	 95%CI:0.75,1.27),	 ICU	 admission	 (OR:1.09;95%CI:0.65,1.81),	
death/ICU	 admission	 (OR:0.67;	 95%CI:0.52,0.86),	 risk	 of	 COVID-19	 infection	
(OR:1.01;	 95%CI:0.93,1.10),	 severe	 infection	 (OR:0.78;	 95%CI:0.53,1.15),	 and	 hos-









the reported clinical outcomes.
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1  | INTRODUC TION
Soon	after	 the	 report	of	 first	clusters	of	COVID-19	cases	 in	China	 in	
December	2019,	concerns	were	raised	among	clinicians	and	investiga-
tors that angio	tensi	n-conve	rting	 enzyme	 inhibitors	 (ACEIs)	 and	 angio 
tensi n receptor	blockers	(ARBs)	might	increase	susceptibility	to	COVID-
19	 infection	and	the	 likelihood	of	severe	and	fatal	COVID-19	 illness.1 
These concerns are based on the concept that angio	tensi	n-conve	
rting	enzym	e	2	 (ACE2),	an	enzyme	potentially	upregulated	by	ACEIs/
ARBs	use,	is	the	viral	entry	receptor	that	COVID-19	uses	to	enter	lung	
cell,2 coupled with the observation of high prevalence of hypertension 
and	other	cardiovascular	comorbidities	among	COVID-19	patients	who	
have poor outcomes.3	Consequently,	it	was	speculated	that	due	to	con-
siderable	prescription	of	ACEIs/ARBs	 to	 treat	 cardiovascular	diseases	
(CVD),	this	would	adversely	affect	outcomes	from	COVID-194 with un-
derlying cardiac and kidney diseases already associated with poorer out-
comes.3,5,6	Consequently,	care	to	avoid	treatments	that	well	add	to	this.
Unsurprisingly,	 discussions	 regarding	 the	 potential	 impact	 of	
ACEIs/	ARBs	have	 resulted	 in	anxiety,	which	might	cause	patients	
and clinicians to discontinue or stop these medications.7 This should 
be avoided as there will be harm from the indiscriminate withdrawal 
of	 ACEIs/ARBs.8 This concern is complicated by uncertainty sur-
rounding	the	upregulation	of	ACE2	by	ACEIs/ARBs.9	Furthermore,	
the	paradoxical	protective	role	of	ACEIs/ARBs	in	COVID-19	patients	
is also being proposed.10 Due to these controversial findings, and 
despite consistent and reassuring recommendations for the contin-
ued	use	of	ACEIs/ARBs	in	COVID-19	patients	issued	by	International	
Societies,11 these concerns remain. We wish to address this as we 
have already seen the impact that inappropriate endorsement of 
treatments	can	have	on	morbidity	and	mortality.	Early	endorsement	
of	hydroxychloroquine	resulted	in	drug	shortages	for	other	 indica-
tions, price hikes, increased adverse drug reactions, and deaths from 
suicides.12,13	 However,	 subsequent	 studies	 failed	 to	 show	 clinical	
benefit	resulting	in	the	World	Health	Organisation	(WHO)	and	the	
National	Institute	of	Health	(NIH)	in	the	USA	stopping	the	hydroxy-
chloroquine	 arm	 in	 their	 studies.14-16 A similar situation has been 
seen with lopinavir/ritonavir.15	 Consequently	 it	 is	 imperative	 that	
any considerations regarding management are evidence based.
We are aware that several observational studies have been con-
ducted	to	address	these	concerns.	However,	these	studies	have	reported	
K E Y W O R D S
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have been associated with lower mortality rates in some studies17,20,24-27 
while others23,28 reported higher mortality rates. We are also aware that 
two recently published systematic reviews29,30 containing 16 studies 
reported	 no	 evidence	 of	 any	 association	 between	 ACEIs/ARBs	 and	












2.1 | Data source and searches
This	 systematic	 review	 and	 meta-analysis	 was	 conducted	 and	
reported	 in	 accordance	 to	 the	 Preferred	 Reporting	 Items	 for	
Systematic	 Reviews	 and	 Meta-Analyses	 (PRISMA)	 statement	
checklist.32 A protocol was drafted and shared with authors but not 
registered in any database as we did not want the submission of our 
findings to be delayed until the study protocol was registered as we 







egy	 used	 in	 the	 database	 searches	 is	 attached	 [File	 S1].	We	 also	
manually searched the reference list of eligible articles to identify 
any further relevant articles.
2.2 | Study selection
Eligibility	 criteria	 included	 original	 research	 studies,	 published	 in	
English,	with	COVID-19	patients	(target	population)	that	reported	the	
effects	of	ACEIs/ARBs	(intervention),	in	comparison	with	non-ACEIs/
ARBs	use	 (comparison),	 on	COVID-19-related	outcomes.	No	 restric-
tions were placed on the reported outcomes or study types. All records 
identified	from	the	search	strategy	were	exported	from	the	databases	
and imported into Covidence®31 whereby duplicate records were re-
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and abstract screening for relevance, followed by selecting records 
for	full-text	screening	and	data	extraction.	At	each	stage,	discrepan-
cies were resolved through discussion until consensus was achieved. A 
third	author	(AK)	verified	the	eligibility	of	the	included	studies.
2.3 | Data extraction and quality assessment
Data	from	the	eligible	studies	were	subsequently	extracted	by	two	
authors	 (NA,	 AK)	 into	 a	 spreadsheet	 including	 information	 on	 the	
study	characteristics	(study	design,	setting,	sample	size,	population,	
exposure-ACEIs/ARBs,	 ACEIs,	 or	 ARBs)	 and	 outcome	measures	 in-
cluding	death,	intensive	care	unit	(ICU)	admission,	risk	of	COVID-19	
infection,	severe	COVID-19	infection,	severe	pneumonia,	hospitaliza-
tion, hospital discharge, use of ventilators, duration of hospital stay, 
septic shock, acute kidney injury, cardiac injury, and hospital readmis-
sion.	Since	the	need	for	using	ventilators	typically	necessitates	ICU	
admission,	 we	 combined	 studies	 that	 reported	 ICU	 admission	 and	
ventilator use as a further composite outcome measure. Two authors 
(NA	and	LA)	independently	conducted	the	assessment	of	risk	of	bias	
using	the	Newcastle-Ottawa	Scale	(NOS)	for	nonrandomized	studies	
which consists of three domains (selection of participants and control 
(if	 applicable),	 comparability	 and	 exposure	or	 outcome),32 whereby 
studies	were	classified	into	good	quality	(3	or	4	stars	in	selection	do-






F I G U R E  2  Forest	plot	depicting	pooled	estimates	for	the	association	between	mortality	and	the	three	levels	of	renin-angiotensin	system	
drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)
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was	resolved	by	involving	a	third	researcher	(AK)	for	discussion	until	a	
consensus	was	reached.	Furthermore,	interrater	reliability	measures	
such as kappa statistic and percentage agreement were also calcu-
lated.	Some	of	the	coauthors	have	used	this	approach	before.34
2.4 | Data synthesis and analysis
For	 each	 study	 outcome	 that	 was	 reported	 by	 more	 than	 one	
study, the results from individual studies were combined statis-
tically	 using	 the	 random-effects	 meta-analysis	 model,	 stratified	
by	the	level	of	exposure	(ACEIs/ARBs,	ACEIs,	ARBs);	whereas	for	
outcomes which were reported by only one study, narrative syn-
thesis	was	 used.	 For	 studies	which	 did	 not	 report	 the	 summary	
statistics and measure of effects, we firstly used the reported 
primary statistics (number of patients with/without the outcomes 
in	both	exposed/unexposed	group)	to	calculate	the	corresponding	
measure	 of	 effects	 (Odds	 ratios-	OR)	 and	 their	 95%	 confidence	
interval	 (95%CI),35	 and	 subsequently	 used	 these	 measure	 of	 ef-
fects	 in	 the	 random-effects	 meta-analysis;	 the	 random-effects	
model was used as it is considered the most appropriate model 
by	most	researchers	since	it	allows	the	results	to	be	generalizable	
to other populations as well as addresses the likely heterogeneity 
between the included studies.36	Several	subgroup	analyses	were	
also	undertaken	to	explore	the	effect	of	potential	confounders	on	
the robustness and sensitivity of combined pooled estimates and 
included subgroup analyses based on whether the reported meas-
ure	of	effects	was	crude	or	adjusted,	whether	the	study	was	peer-
reviewed	or	not,	the	study's	methodological	quality	as	per	the	risk	
of bias assessment was performed as well as the continent where 
TA B L E  3  Meta-analyses	pooled	estimates	with	95%CI	of	the	effects	of	ACEIs/ARBs	on	COVID-19	related	clinical	outcomes
Outcomes ACEIs/ARBs P-value ACEIs P-value ARBs P-value
Death 0.973	(0.746,	1.269) 0.84 1.049	(0.751,	1.464) 0.781 1.181	(0.983,	1.418) 0.076
Number of studies 11 2 2
I-squared 65.5% 0.001 26.3% 0.244 0.6% 0.316
ICU 1.086	(0.652,	1.809) 0.75 0.945	(0.65,	1.376) 0.769 1.49	(1.126,	1.973) 0.005
Number of studies 6 3 3
I-squared	(P-value) 84.4% <0.001 4.9% 0.349 0% 0.475
Death/ICU 0.67	(0.524,	0.857) 0.001 0.888	(0.694,	1.136) 0.345 0.83	(0.65,	1.061) 0.136
Number of studies 3 2 2
I-squared	(P-value) 0% 0.572 0% 0.726 0% 1.000
Risk	of	COVID-19 1.014	(0.935,	1.099) 0.745 1.133	(1.417,	21.27) 0.273 0.557	(0.107,	2.895) 0.46
Number of studies 7 3 2
I-squared	(P-value) 0% 0.75 0% 0.457 97.9% <0.001
Severe	COVID-19 0.782	(0.529,	1.154) 0.215 0.718	(0.264,	1.955) 0.517 0.506	(0.247,	1.036) 0.062
Number of studies 6 3 3
I-squared	(P-value) 43.3% 0.117 0% 0.799 18% 0.296
Severe	pneumonia 1.285	(0.237,	6.958) 0.771 NA NA
Number of studies 2
I-squared	(P-value) 57.5% 0.125
Hospitalization 1.153	(0.806,	1.65) 0.436 1.077	(0.791,	1.465) 0.638 0.907	(0.74,	1.112) 0.349
Number of studies 5 5 5
I-squared	(P-value) 74.5% 0.003 63.7% 0.026 0% 0.965
Hospital	discharge 1.213	(0.739,	1.991) 0.446 NA NA
Number of studies 3
I-squared	(P-value) 82.2% 0.004
Ventilator use 1.492	(0.804,	2.77) 0.205 1.014	(0.03,	34.758) 0.994 0.985	(0.084,	11.57) 0.990
Number of studies 4 2 2
I-squared	(P-value) 80.7% 0.001 64.7% 0.092 88.6% 0.003
ICU/ventilator	use 1.225	(0.836,	1.795) 0.298 1.149	(0.554,	2.382) 0.709 1.467	(0.907,	2.373) 0.118
Number of studies 10 5 5
I-squared	(P-value) 83.2% <0.001 75.2% 0.003 66.2% <0.001
Note: NA,	not	applicable	indicating	no	enough	studies	to	perform	meta-analyses
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TA B L E  4  Subgroup	meta-analyses	pooled	estimates	with	95%CI	of	the	effects	of	ACEIs/ARBs	on	COVID-19	related	clinical	outcomes
Death (n = 15)
ACEIs/ARBs ACEIs ARBs
Adjusted outcome measure
Adjusted OR 0.973	(0.260,	1.660) NA NA
Crude OR 1.048	(0.772,	1.424) 1.049	(0.751,	1.464)* 1.181	(0.983,	1.418)*
Number of studies 2	vs	9 0 vs 2 0 vs 2
Peer-reviewed	article?
Yes 0.894	(0.522,	1.533) NA NA
No 1.004	(0.716,	1.408) 1.049	(0.751,	1.464)* 1.181	(0.983,	1.418)*
Number of studies 6	vs	5 0 vs 2 0 vs 2
Study's	quality
Good	quality 1.113	(0.884,	1.400) NA NA
Poor	quality 0.915	(0.627,	1.336) 1.049	(0.751,1.464)* 1.181	(0.983,1.418)*
Number of studies 2	vs	9 0 vs 2 0 vs 2
Study's	country
Europe 1.176	(0.932,	1.483) 1.523	(0.728,	3.185) 1.645	(0.838,	3.229)
USA 0.92	(0.494,	1.714) 0.97	(0.811,	1.161) 1.15	(0.954,	1.386)
Asia 0.753	(0.401,	1.413) NA NA
Number of studies 3 vs 2 vs 6 1 vs 1 vs 0 1 vs 1 vs 0
ICU admission (n = 12)
Adjusted outcome measure
Adjusted OR NA NA NA
Crude OR 1.086	(0.652,	1.809)* 0.945	(0.650,	1.376)* 1.490	(1.126,	1.973)*
Number of studies 0 vs 6 0 vs 3 0 vs 3
Peer-reviewed	article?
Yes 1.560	(1.234,	1.972) NA NA
No 0.762	(0.295,	1.972) 0.945	(0.650,	1.376)* 1.490	(1.126,	1.973)*
Number of studies 3 vs 3 0 vs 3 0 vs 3
Study's	quality
Good	quality 0.364	(0.224,	0.591) NA NA
Poor	quality 1.445	(0.133,	1.843) 0.945	(0.650,	1.376)* 1.490	(1.126,	1.973)*
Number of studies 1	vs	5 0 vs 3 0 vs 3
Study's	country
Europe 0.495	(0.253,	0.966) 0.945	(0.650,	1.376)* 1.490	(1.126,	1.973)*
USA 1.591	(1.277,	1.983) NA NA
Asia 1.439	(0.600,	3.453) NA NA
Number of studies 2 vs 3. vs 1 3 vs 0. vs 0 3 vs 0. vs 0
Death/ICU admission (n = 7)
Adjusted outcome measure
Adjusted OR 0.630	(0.471,	0.842) NA NA
Crude OR 0.783	(0.493,	1.243) 0.888	(0.694,	1.136)* 0.830	(0.650,	1.061)*
Number of studies 1 vs 2 0 vs 2 0 vs 2
Peer-reviewed	article?
Yes NA 0.910	(0.690,	1.210) 0.830	(0.630,	1.100)
No 0.670	(0.524,	0.857)* 0.820	(0.490,	1.360) 0.830	(0.500,	1.400)
Number of studies 0 vs 3 1 vs 1 1 vs 1
(Continues)
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Death/ICU admission (n = 7)
Study's	quality
Good	quality 0.630	(0.471,	0.842) 0.910	(0.687,	1.205) 0.830	(0.628,	1.097)
Poor	quality 0.783	(0.493,	1.243) 0.820	(0.492,	1.366) 0.830	(0.496,	1.389)
Number of studies 1 vs 2 1 vs 1 1 vs 1
Study's	country
Europe 0.679	(0.520,	0.887) 0.888	(0.694,	1.136) 0.830	(0.650,	1.061)
USA NA NA NA
Asia 0.599	(0.251,	1.430) NA NA
Number of studies 2 vs 0 vs 1 2 vs 0 vs 0 2 vs 0 vs 0
Risk of COVID-19 infection (n = 12)
Adjusted outcome measure
Adjusted OR 1.190	(0.962,	1.473) 1.180	(0.867,	1.605) 1.290	(0.930,	1.790)
Crude OR 0.986	(0.904,	1.077) 1.015	(0.620,	1.662) 0.240	(0.170,	0.340)
Number of studies 1 vs 6 1 vs 2 1 vs 1
Peer-reviewed	article?
Yes 1.030	(0.941,	1.128) 1.180	(0.867,	1.605) 1.290	(0.930,	1.790)
No 0.948	(0.790,	1.138) 1.015	(0.620,	1.662) 0.240	(0.170,	0.340)
Number of studies 4 vs 3 1 vs 2 1 vs 1
Study's	quality
Good	quality NA 0.650	(0.265,	1.597) 0.240	(0.170,	0.339)
Poor	quality 1.014	(0.935,	1.099)* 1.176	(0.933,	1.481) 1.290	(0.930,	1.790)
Number of studies 0 vs 7 1 vs 2 1 vs 1
Study's	country
Europe 0.956	(0.695,	1.316) 1.170	(0.825,	1.660) NA
USA 0.99	(0.901,	1.087) NA NA
Asia 1.131	(0.942,	1.358) 1.023	(0.622,	1.684) 0.557	(0.107,	2.895)*
Number of studies 1 vs 3 vs 3 1 vs 0 vs 2 0 vs 0 vs 2
Severe COVID-19 (n = 12)
Adjusted outcome measure
Adjusted OR 0.480	(0.108,	2.130) NA NA
Crude OR 0.795	(0.525,	1.206) 0.718	(0.264,	1.955)* 0.506	(0.247,	1.036)*
Number of studies 1	vs	5 0 vs 3 0 vs 3
Peer-reviewed	article?
Yes 0.895	(0.614,	1.303) 0.595	(0.067,	5.296) 0.333	(0.069,	1.607)
No 0.387	(0.144,	1.040) 0.755	(0.245,	2.328) 0.509	(0.176,	1.474)
Number of studies 4 vs 2 1 vs 2 1 vs 2
Study's	quality
Good	quality NA 1.230	(0.190,	7.946) 0.770	(0.362,	1.638)
Poor	quality 0.782	(0.529,	1.154)* 0.578	(0.176,	1.893) 0.283	(0.101,	0.792)
Number of studies 0 vs 6 1 vs 2 1 vs 2
Study's	country
Europe 0.480	(0.108,	1.130) NA NA
USA 0.994	(0.820,	1.205) NA NA
Asia 0.513	(0.216,	1.216) 0.718	(0.264,	1.955)* 0.506	(0.247,	1.036)*
Number of studies 1 vs 1 vs 4 0 vs 0 vs 3 0 vs 0 vs 3
(Continues)
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Severe pneumonia (n = 2)
Adjusted outcome measure
Adjusted OR 0.410	(0.050,	3.275) NA NA
Crude OR 2.462	(0.939,	6.452) NA NA
Number of studies 1 vs 1
Peer-reviewed	article?
Yes NA NA NA
No 1.285	(0.237,	6.958) NA NA
Number of studies 0 vs 2
Study's	quality
Good	quality NA NA NA
Poor	quality 1.285	(0.237,	6.958) NA NA
Number of studies 0 vs 2
Study's	country
Europe NA NA NA
USA NA NA NA
Asia 1.285	(0.237,	6.958)
Number of studies 0 vs 0 vs 2
Hospitalization (n = 15)
Adjusted outcome measure
Adjusted OR 1.300	(1.113,	1.518) 1.170	(0.900,	1.520) 1.0	(0.702,	1.424)
Crude OR 1.032	(0.561,	1.897) 1.056	(0.684,	1.631) 0.865	(0.674,	1.109)
Number of studies 1 vs 4 1 vs 4 1 vs 4
Peer-reviewed	article?
Yes 1.930	(1.377,	2.705) NA NA
No 0.977	(0.647,	1.474) 1.077	(0.791,	1.465)* 0.907	(0.740,	1.112)*
Number of studies 1 vs 4 0	vs	5 0	vs	5
Study's	quality
Good	quality 1.300	(1.113,	1.518) NA NA
Poor	quality 1.032	(0.561,	1.897) 1.077	(0.791,	1.465)* 0.907	(0.740,	1.112)*
Number of studies 1 vs 4 0	vs	5 0	vs	5
Study's	country
Europe 0.907	(0.413,	1.992) 1.181	(0.843,	1.656) 0.922	(0.721,	1.179)
USA 1.589	(1.033,	2.443) 0.77	(0.527,	1.124) 0.877	(0.611,	1.258)
Asia 0.569	(0.178,	1.815) NA NA
Number of studies 2 vs 2 vs 1 4 vs 1 vs 0 4 vs 1 vs 0
Hospital discharge (n = 3)
Adjusted outcome measure
Adjusted OR NA NA NA
Crude OR 1.213	(0.739,	1.991) NA NA
Number of studies 0 vs 3
Peer-reviewed	article?
Yes 0.844	(0.663,	1.074) NA NA
No 1.513	(1.184,	1.935) NA NA
Number of studies 1 vs 2
(Continues)
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tic,37 indicating whether variability is more likely due to study het-
erogeneity or chance. Negative I2	values	were	set	to	zero,	hence	
I2	 values	 ranged	between	0%	and	100%	with	0%	 indicating	 lack	
of	 heterogeneity,	 whereas	 25%,	 50%,	 and	 75%	 indicating	 low,	
moderate and high heterogeneity, respectively.37	Publication	bias	
was	assessed	using	funnel	plots	and	Egger's	asymmetry	test38 for 
those outcomes where >10 studies were included in the analysis 
as recommended by Cochrane guidelines.39	Data	were	 analyzed	
using	STATA	12.








studies was 61 ±	 9.6	years	 and	men	 represented	52.24%	of	 them	
(Table	1).	Twenty-one	studies	(77.8%)	focused	on	comparing	COVID-
19-related	outcomes	between	ACEI/ARB	users	vs	nonusers	among	
patients	 with	 COVID-19	 while	 the	 remaining	 six	 studies	 (22.2%)	
focused	on	comparing	outcomes	between	ACEIs/ARBs	users	in	pa-
tients	with	and	without	COVID-19	infection	(Table	1).	ACEIs/ARBs	in	
the included studies were indicated for a wide range of chronic con-
ditions such as hypertension, coronary artery diseases, heart failure, 
diabetes, or chronic kidney disease.
Hospital discharge (n = 3)
Study's	quality
Good	quality NA NA NA
Poor	quality 1.213	(0.739,	1.991) NA NA
Number of studies 0 vs 3
Study's	country
Europe NA NA NA
USA 1.122	(0.641,	1.964) NA NA
Asia 1.862	(0.659,	5.26) NA NA
Number of studies 0 vs 2 vs 1
Ventilator use (n = 8)
Adjusted outcome measure
Adjusted OR NA NA NA
Crude OR 1.492	(0.804,	2.770) 1.014	(0.03,	34.758) 0.985	(0.084,	11.57)
Number of studies 0 vs 4 0 vs 2 0 vs 2
Peer-reviewed	article?
Yes 1.141	(0.606,	2.150) 0.078	(0.001,	6.878) 0.251	(0.053,	1.185)
No 3.338	(2.035,	5.475) 3.603	(1.889,	6.872) 3.129	(1.699,	5.761)
Number of studies 1 vs 3 1 vs 1 1 vs 1
Study's	quality
Good	quality NA NA NA
Poor	quality 1.492	(0.804,	2.770) 1.014	(0.030,	34.758) 0.985	(0.084,	11.570)
Number of studies 0 vs 4 0 vs 2 0 vs 2
Study's	country
Europe 3.338	(2.035,	5.475) 3.603	(1.889,	6.872) 3.129	(1.699,	5.762)
USA 1.524	(1.171,	1.985) NA NA
Asia 0.202	(0.043,	0.947) 0.078	(0.001,	6.469) 0.251	(0.053,	1.187)
Number of studies 1 vs 2 vs 1 1 vs 0 vs 1 1 vs 0 vs 1
*Indicates that the pooled estimate is the same as the overall analyses because all the studies were in one group; NA: not applicable indicating that 
no	studies	were	available	to	perform	meta-analyses	for	these	outcomes;	
TA B L E  4   (Continued)
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In	 terms	 of	 outcomes,	 nine	 studies	 (33.3%)	 reported	 three	
to	 five	 COVID-19-related	 outcomes,20,23,25,26,40-44 while another 
nine	studies	 (33.3%)	 reported	only	 two	outcomes17,19,22,24,27,45-48 
with	 another	 one-third	 reported	 only	 one	 outcome.19,22,29,46-51 
Overall,	 the	 27	 studies	 reported	 data	 on	 15	 unique	 outcomes	
including death in 12 studies,18,21,28,49-54	 ICU	admission	 in	 seven	
studies,23,25,40-44	 death/ICU	 admission	 as	 a	 composite	 outcome	
in four studies,21,40,45,54	 risk	 of	 acquiring	 COVID-19	 infection	 in	
nine studies,22,25,26,42-44,48,49,53	 risk	 of	 severe	 COVID-19	 infec-
tion in seven studies,17-19,22,24,48,50 risk of severe pneumonia in 
two studies,26,51	 risk	 of	 hospitalization	 in	 eight	 studies,26,42-47,52 
hospital discharge in three studies,23,26,27 use of ventilator in four 
studies,19,23,41,44 duration of hospital stay in two studies,25,26 and 
each	of	acute	respiratory	distress	syndrome	(ARDS),	septic	shock,	
cardiac shock, acute kidney injury,20 and hospital readmission23 
in	one	 study,	 respectively.	 In	 terms	of	 the	exposure,	 the	effects	
of	 ACEIs	 and	 ARBs	were	 assessed	 as	 one	 class	 (ACEIs/ARBs)	 in	
17	studies	(63%),17,20,22-28,40,43,44,47,50,51,53,54 as separate classes in 
five	studies	(18.5%)	52,	74,	78,	80,	84),	and	both	as	one	and	sepa-
rate classes in another five studies.18,19,41,45,49
The majority of the 27 eligible studies were conducted in Asia 
(44.4%,	n	=	12	with	10	studies	from	China,	one	each	from	Korea	and	
Israel),	 followed	 by	 nine	 studies	 (33.3%)	 from	Europe	 (four	 in	 Italy,	
three	in	the	United	Kingdom	and	one	each	from	France	and	Belgium)	
and	 the	 remaining	 six	 (22.3%)	 from	 the	USA.	 Furthermore,	 the	 re-
ported measure of effects were crude/unadjusted measures in the 
majority	of	the	studies	(77.8%,	n	=	21)18,19,21-28,40-46,48,53,54; with most 
of	 them	 (59.3%,	n	=	 16)	being	nonpeer-reviewed	articles	published	
as	 preprints	 on	 medRivix,24,26,27,40-43,45-48,50-54 and only four rated 
as	 a	 good	 quality	 studies	 based	 on	 the	Newcastle-Ottawa	Quality	
Assessment risk of bias21,40,47,48	(Table	2).	Results	from	the	interrater	
reliability measures indicated a substantial agreement between the 
F I G U R E  3  Forest	plot	depicting	pooled	estimates	for	the	association	between	Intensive	Care	Unit	admission	and	the	three	levels	of	
renin-angiotensin	system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 72.2%, p = 0.000)
Benelli et al., (April 2020)
Richardson et al., (April 2020)
ARBs
Subtotal  (I-squared = 4.9%, p = 0.349)
Dauchet et al., (May 2020)
Rentsch et al., (April 2020)
Subtotal  (I-squared = 0.0%, p = 0.475)
Benelli et al., (April 2020)
Dauchet et al., (May 2020)
Subtotal  (I-squared = 84.4%, p = 0.000)
ID
Benelli et al., (April 2020)
Dauchet et al., (May 2020)
ACEIs
Mehta et al., (May 2020)
Yang et al., (May 2020)
ACEIs/ARBs
Dauchet et al., (May 2020)












































3.2.1 | Death and ICU admission
Among pertinent studies, there was insignificant association 
between	 mortality	 and	 ACEIs/ARBs	 (OR:	 0.97;	 95%CI:	 0.75	
1.27),	 ACEIs	 (OR:1.05;	 95%CI:	 0.75,	 1.46),	 or	 ARBs	 (OR:1.18,	
95%CI:	0.98,	1.42)	(Figure	2;	Table	3),	regardless	of	the	studies’	
country,	 quality,	 peer-review	 status	 or	 crude/adjusted	 meas-
ure	 of	 effect	 (File	 S2;	 Table	 4).	 Similarly,	 there	 was	 an	 insig-




group analyses indicated different results. A significantly lower 




95%CI:	 1.28,	 1.98),	 peer-reviewed	 studies	 (OR:1.56;	 95%CI:	





lower	 association	with	 ACEIs	 (OR:0.89;	 95%CI:	 0.69,	 1.14)	 or	
ARBs	(OR:	0.83;	95%CI:	0.65,	1.06),	regardless	of	any	subgroup	
analysis	for	ACEIs	and	ARBs	(Figure	4;	Table	3).	The	subgroup	
analyses	 for	 ACEIs/ARBs,	 however,	 showed	 a	 significantly	
lower	 association	 of	 death/ICU	 admission	 with	 ACEIs/ARBs	
only	 among	 European	 studies	 (OR:	 0.68;	 95%CI:	 0.52,	 0.89),	
good	quality	studies	(OR:0.63;	95%CI:	0.47,	0.84),	and	studies	
which	 reported	 adjusted	measure	 of	 effect	 (OR:0.63;	 95%CI:	
0.47,	0.84)	(File	S4;	Table	4).
F I G U R E  4  Forest	plot	depicting	pooled	estimates	for	the	association	between	the	composite	outcome	of	mortality/	Intensive	Care	
admission	and	the	three	levels	of	renin-angiotensin	system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 0.0%, p = 0.678)
Mancia et al., (May 2020)
ID
Study
Subtotal  (I-squared = 0.0%, p = 0.572)
Bravi et al., (May 2020)
Subtotal  (I-squared = 0.0%, p = 0.726)
Subtotal  (I-squared = 0.0%, p = 1.000)
ACEIs
Mancia et al., (May 2020)
Bravi et al., (May 2020)
ACEIs/ARBs
Bean et al., (May 2020)
Bravi et al., (May 2020)



























Death or ICU admission
1.251 3.98
Odds ratio
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3.2.2 | Risk of acquiring COVID-19 infection, severe 
COVID-19 infection and severe pneumonia
The overall pooled analysis of nine studies indicated insignificant 







peer-reviewed	 studies,	 good-quality	 studies	 and	 studies	 which	
reported	crude	measure	of	effects	(OR:	0.24;	95%CI:	0.17,	0.34)	
(File	 S5C;	 Table	 4).	 Similarly,	 in	 a	 pooled	 analysis	 of	 seven	 and	
two studies, insignificant association was observed between the 
risk	 of	 developing	 severe	 COVID-19	 infection,	 severe	 pneumo-




3.2.3 | Hospitalization, hospital discharge and 
duration of hospital stay
In a pooled analysis of eight and three studies, there was no significa-





among	 studies	 conducted	 in	 the	 USA	 (OR:1.59;	 95%CI:	 1.03,	 2.44),	
peer-reviewed	studies	(OR:1.93,	95%CI:	1.38,	2.71),	good	quality	stud-
ies and studies which reported adjusted measure of effect (OR:1.30, 
95%CI:	1.10,	1.50)	(File	S7;	Table	4).	Contrastingly,	a	significantly	higher	
rate	 of	 hospital	 discharge	 was	 observed	 with	 ACEIs/ARBs	 but	 only	
F I G U R E  5  Forest	plot	depicting	pooled	estimates	for	the	association	between	risk	of	acquiring	COVID-19	infection	and	the	three	levels	
of	renin-angiotensin	system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 85.0%, p = 0.000)
Yan et al., (April 2020)
Raisi-Estabragh  et al., May 2020)
Chodick et al., (May 2020)
Subtotal  (I-squared = 0.0%, p = 0.750)
Mehta et al., (May 2020)
ACEIs
Subtotal  (I-squared = 97.9%, p = 0.000)
Zeng et al., (April 2020)
Subtotal  (I-squared = 0.0%, p = 0.457)
ACEIs/ARBs
Reynolds et al., (May 2020)
Study
Rentsch et al., (April 2020)
Dauchet et al., (May 2020)
Yang et al., (May 2020)
Yan et al., (April 2020)
Chodick et al., (May 2020)
ARBs
ID




































Risk of COVID-19 infection
1.107 9.33
Odds ratio
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among	nonpeer-reviewed	articles	(OR:1.51;	95%CI:	1.18,	1.93)	(File	S8;	
Table	4).	Two	studies	reported	data	on	the	duration	of	hospital	stay.	
Both	were	in	favor	of	ACEIs/ARBs	with	Yang	et	al25 reporting a signifi-
cant	reduction	in	the	mean	duration	of	hospital	stay	of	2.3	days	(95%CI:	
−3.61,	−0.99)	with	ACEIs/ARBs	while	Zeng	et	al26 reported a lower me-
dian	duration	of	hospital	stay	of	21	days	(IRQ:	15-25)	with	ACEIs/ARBs	
versus	22	days	(IQR:	16-28)	with	non-ACEI/ARB	use.
3.2.4 | Use of a ventilator
Among pertinent studies, there was no significant association 
between	 these	 outcomes	 and	 the	 use	 of	 ACEIs/ARBs	 (OR:1.49;	
95%CI:	 0.80,	 2.77;	OR:	 1.26;	 95%CI:	 0.84,	 1.80),	 ACEIs	 (OR:1.01;	




5.48)	 and	 the	USA	 (OR:1.52;	 95%CI:1.17,	 1.98)	 in	 contrast	 to	 sig-
nificantly	lower	odds	among	those	from	Asia	(OR:0.2;	95%CI:	0.04,	




Zhang et al21 reported a significantly lower rate of septic shock 
(HR:	0.32;	95%CI:	0.13,	0.8)	as	well	as	nonsignificant	lower	rate	of	
ARDS	(HR:	0.65;	95%CI:	0.41,	1.04),	acute	kidney	injury	(HR:0.78;	
95%CI:	 0.37,	 1.65),	 and	 cardiac	 injury	 (HR:	 0.76;	 95%CI:	 0.44,	
1.32)	 among	ACEI/ARB	 users.	 Furthermore,	 Richardson	 et	 al,24 
reported	 lower	 odds	 of	 hospital	 readmission	 with	 ACEIs/ARBs	
(OR:	0.77;	95%CI:	0.30,	1.94),	albeit	nonsignificant.
F I G U R E  6  Forest	plot	depicting	pooled	estimates	for	the	association	between	developing	severe	COVID-19	infection	and	the	three	
levels	of	renin-angiotensin	system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 26.4%, p = 0.185)
ID
Liu et al., (March 2020)
Li et al., (April 2020)
ARBs
Liu et al., (March 2020)
Subtotal  (I-squared = 43.3%, p = 0.117)
Yan et al., (April 2020)
ACEIs/ARBs
Meng el al., (March 2020)
Reynolds et al., (May 2020)
Feng et al., (April 2020)
Feng et al., (April 2020)
Liu et al., (March 2020)
Subtotal  (I-squared = 0.0%, p = 0.799)
Subtotal  (I-squared = 18.0%, p = 0.296)
ACEIs
Feng et al., (April 2020)
DeSpiegeleer et al., (May 2020)
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3.3 | Publication bias
Results	from	the	funnel	plot	(File	S10)	and	Egger's	asymmetry	test	











positive	 impact	were	observed	 in	terms	of	 lower	odds	of	death/ICU	
admission, as a composite outcome, and a higher rate of hospital dis-





Our study findings also showed no significant association be-
tween	ACEIs/ARBs	and	mortality,	 severe	COVID-19	 infection,	or	
positive	 tests	 for	 COVID-19,	 in	 agreement	 with	 two	 previously	
published systematic reviews.29,30 This was despite the inclusion of 
more recently published studies,18,27,40,41,49,50,53 which implies con-
sistency of evidence. This is encouraging given the controversies 
F I G U R E  7  Forest	plot	depicting	pooled	estimates	for	the	association	between	hospitalization	and	the	three	levels	of	renin-angiotensin	
system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 61.7%, p = 0.001)
Bravi et al., (May 2020)
Bravi et al., (May 2020)
Dauchet et al., (May 2020)
Dauchet et al., (May 2020)
Subtotal  (I-squared = 74.5%, p = 0.003)
ARBs
Dauchet et al., (May 2020)
Study
Subtotal  (I-squared = 63.7%, p = 0.026)
Dauchet et al., (May 2020)
Khera et al.,
ACEIs
Bravi et al., (May 2020)
Subtotal  (I-squared = 0.0%, p = 0.965)
Khawaja et al., (May 2020)
Khawaja et al., (May 2020)
Khera et al.,
Zeng et al., (April 2020)
Rentsch et al., (April 2020)
Rossi et al., (April 2020)
ID
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surrounding	 hydroxychloroquine.	 Furthermore,	 these	 nonsignif-
icant	 associations	 were	 also	 observed	 for	 additional	 COVID-19-
related	 outcomes	 including	 ICU	 admission,	 hospitalization,	 and	
hospital	 discharge.	However,	 unlike	 the	 previous	 two	 systematic	
reviews,29,30 our study found evidence of associations between 
ACEI/ARB	use	and	certain	COVID-19	clinical	outcomes.	While	the	
pooled estimate of the subgroup analyses indicated a higher odds 
of	 ICU	 admission	with	 ACEIs/ARBs	 among	 studies	 conducted	 in	
the	USA23,43,44	and	peer-reviewed	studies,23,25,44 all these studies 
were	of	poor	quality	and	none	performed	adjusted	analyses	to	ac-
count for potential confounders. Confounding by indication is of 
particular concern with comorbidities such as CVD and diabetes 
associated	with	more	severe	COVID-19	morbidity	and	mortality.4-6 
Similarly,	 the	 observed	 significant	 associations	 between	 ACEIs/
ARBs	use	and	high	odds	of	ventilator	use	and	hospital	discharge	
rates	were	from	Benelli	et	al41 and Ip et al27 and Zeng et al,26 re-
spectively,	all	of	which	were	nonpeer-reviewed,	of	poor	quality	and	
used	crude	analyses.	Similarly,	the	studies	in	the	pooled	analyses	
that	 showed	 significant	 association	 of	ARBs	 use	 and	 ICU	 admis-
sion,41,42	lower	risk	of	acquiring	COVID-19	infection,48 and severe 
infection18,19	 were	 of	 poor	 quality,	 used	 unadjusted/crude	 anal-
yses,	 and/or	 nonpeer-reviewed.	 In	 terms	 of	 duration	 of	 hospital	
stay, Yang et al25 and Zeng et al26 both reported a reduction in hos-
pital	stay	with	ACEIs/ARBs;	however,	 it	was	not	possible	to	com-
bine	them	in	the	meta-analysis	as	they	used	a	different	measure	of	
effects with the former reporting the outcome as a mean differ-
ence with the latter as a median.
On	the	other	hand,	our	study	findings	showed	some	high-qual-
ity	evidence	on	the	association	of	ACEIs/ARBs	and	higher	odds	of	
hospitalization	but	 lower	 odds	of	 death/ICU	 admission	 (as	 a	 com-
posite	 endpoint).	 A	 higher	 odd	 of	 hospitalization	was	 observed	 in	
the	subgroup	analyses	of	studies	conducted	in	the	USA43,44 although 
it	 should	be	noted	that	 there	was	some	heterogeneity	 (57.7%)	be-
tween	the	USA	studies,	used	adjusted	analyses,47	peer-reviewed44 
and	of	good	quality47;	whereas	the	studies	for	lower	death/ICU	ad-








regulation consistently in cardiac and renal tissues in response to 
ARBs	therapy	but	not	ACEIs4,56; this observed difference between 
ARBs	and	ACEIs	has	been	suggested	to	be	due	to	the	increased	level	
of	 angiotensin	 II,	which	 occurs	 following	ARBs	 treatment	 but	 not	
ACEIs,	which	in	turn	imposes	an	increased	substrate	load	on	ACE2	
enzyme	requiring	 its	upregulation.57 Importantly, it should be em-
phasised	that	evidence	of	ACEIs/ARBs	induced	ACE2	upregulation	
F I G U R E  8  Forest	plot	depicting	pooled	estimate	for	the	association	between	hospital	discharge	and	ACEIs/ARBs	use
NOTE: Weights are from random effects analysis
Overall  (I-squared = 57.5%, p = 0.125)
Feng et al., (April 2020)




























substrates, is unlikely to result in any meaningful differences in 





COVID-19	infection.25 Together, these evidences indicate that the 
concerns	 around	ACEIs/ARBs	 use	 in	COVID-19	 patients	might	 be	
unjustifiable.	On	the	other	hand,	the	protective	effect	hypothesizes	
on	 ACEIs/ARBs	 protecting	 against	 lung	 injury,	 through	 blockage	
of the harmful angio	tensi	n	 II-	 AT1R	 axis,	which	 gets	 activated	 by	
impairment	of	ACE2	activity	as	a	result	of	ACE2’s	downregulation	
results	 from	 ACE2’s	 binding	 with	 COVID-19	 virus;	 additionally,	
the corresponding increase in angiotensin II and angiotensin I, due 
to	ACEIs/ARBs	use,	would	 activate	 the	protective	 axis	 and	hence	
reduce	COVID-19	viral	pathogenicity.4	Genetic	ACE2	polymorphism	
among some individuals has been also suggested as potential fac-
tor	explaining,	at	least	partially,	the	harmful	effects	on	ACEIs/ARBs	
among	COVId-19	patients58; but this needs further investigation.
4.1 | Strengths and limitation
We believe this study is the first to provide a systematic, comprehen-
sive	and	updated	evaluation	of	the	effects	of	ACEIs/ARBs	on	all	the	
reported	COVID-19-related	 clinical	 outcomes	 including	 exploration	
of	interclass	differences	between	ACEIs	and	ARBs	as	well	as	multiple	
subgroup analyses, although we do acknowledge that some of the 
subgroup	analyses	only	had	1-2	studies	for	some	of	the	studied	out-
comes	 such	as	 ICU	admission	and	Death/ICU	admission.	However,	
our	 study	 has	 limitations.	 Since	 all	 included	 studies	were	 observa-
tional studies, the effect of confounding including residual confound-
ers cannot be ruled out. There is also the possibility that new studies 
F I G U R E  9  Forest	plot	depicting	pooled	estimates	for	the	association	between	use	of	ventilator	and	the	three	levels	of	renin-angiotensin	
system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 77.4%, p = 0.000)
Study
Subtotal  (I-squared = 88.6%, p = 0.003)
Benelli et al., (April 2020)
Benelli et al., (April 2020)
Subtotal  (I-squared = 80.7%, p = 0.001)
Benelli et al., (April 2020)
Subtotal  (I-squared = 64.7%, p = 0.092)
Feng et al., (April 2020)
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but	 only	 low-quality	 evidence	 for	 higher	 ICU	 admission,	 ventilator	
use,	 hospital	 discharge	 and	 lower	 duration	 of	 hospital	 stay	 exists.	
Furthermore,	there	 is	evidence,	albeit	of	poor	quality,	of	differences	
between	ACEIs	 and	ARBs	with	 the	 latter	 being	 associated	with	 sig-
nificantly	higher	ICU	admission	but	lower	COVID-19	infection	risk	and	




6  | NOMENCL ATURE OF TARGETS AND 
LIGANDS
Key	 protein	 targets	 and	 ligands	 in	 this	 article	 are	 hyperlinked	 to	
corresponding entries in http://www.guide topha rmaco logy.org, 
F I G U R E  1 0  Forest	plot	depicting	pooled	estimates	for	the	association	between	use	of	ventilator/Intensive	Care	Unit	admission	and	the	
three	levels	of	renin-angiotensin	system	drug	exposure	(ACEIs/ARBs,	ACEIs,	ARBs)




Overall  (I-squared = 77.1%, p = 0.000)
Benelli et al., (April 2020)
Yang et al., (May 2020)
Rentsch et al., (April 2020)
Bean et al., (May 2020)
Dauchet et al., (May 2020)
Dauchet et al., (May 2020)
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Benelli et al., (April 2020)
Dauchet et al., (May 2020)
Mehta et al., (May 2020)
ARBs
Benelli et al., (April 2020)
Feng et al., (April 2020)
Benelli et al., (April 2020)
ACEIs
Richardson et al., (April 2020)
Dauchet et al., (May 2020)
Benelli et al., (April 2020)
Subtotal  (I-squared = 66.2%, p = 0.019)
Study
Subtotal  (I-squared = 83.2%, p = 0.000)
Mehta et al., (May 2020)
Feng et al., (April 2020)
Feng et al., (April 2020)
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Subtotal  (I-squared = 75.2%, p = 0.003)
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the	 common	 portal	 for	 data	 from	 the	 IUPHAR/BPS	 Guide	 to	
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